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Summary The prognostic value of Ki-67 immunohistochemical labelling was evaluated in 327 operable
primary carcinomas of the breast. The follow-up time was up to 4 years (mean 2.7 years). The disease-free
survival in Ki-67 positive patients was shorter than in Ki-67 negative patients (P<0.005). By combining the
Ki-67 expression with ER receptors and stage, subgroups with a different disease-free survival were identified.
In stage II patients there was a significant difference (P<0.005) in disease-free survival between Ki-67
positive/ER negative and Ki-67 negative/ER positive patients. In node negative patients there was no such
difference. The disease-free survival according to different prognostic factors, stage, ER and node status, were
separately examined using a Cox's proportional hazards model. ER (P<0.0001), the Ki-67 (P<0.02), tumour
size (P<0.0001) and nodal status (P<0.006) were independent prognostic factors. We conclude that the
potential value of Ki-67 labelling for prognostic evaluation of patients with breast carcinoma is good.
The increasing number of options for the treatment of breast
carcinoma has made the prognostic evaluation of the disease
even more important. The histologic criteria for grading of
the carcinoma into poorly differentiated and well
differentiated ones was established already in 1957 (Bloom &
Richardson, 1957). Patients with poorly differentiated
tumours have a shorter relapse-free survival than those with
differentiated ones. Node positivity also decreases the
disease-free survival time (Du-Toit et al., 1990; Fisher et al.,
1983). Methods of 3H Thymidine incorporation (Silvestrini et
al., 1974) and flow cytometry (Kallioniemi et al., 1987) are
well established but complex procedures giving prognostic
information. It is desirable to find easier methods for the
prognostic evaluation of breast carcinoma. In this respect the
introduction of a mouse monoclonal antibody Ki-67 by
Gerdes et al. (1983) simplified the measurement of pro-
liferative activity in breast carcinoma tissue. The monoclonal
antibody labels a still unknown nuclear antigen in pro-
liferating cells. Cell nuclei in the resting stage (GO) are not
stained. Ki-67 immunoreactivity has been studied in several
types of carcinoma, e.g. in breast carcinoma (Barnard et al.,
1987; Gasparini et al., 1992; Locker et al., 1992), in bladder
carcinoma (Fontana et al., 1992), in carcinoma of the pros-
tate (Thompson et al., 1992) and in colon carcinoma (Pors-
chen et al., 1991). In this study the prognostic value of Ki-67
immunohistochemistry is evaluated by a follow-up of 327
patients with primary breast carcinomas operated between
1988 and 1990.
Patients and methods
A total of 327 patients operated for primary breast car-
cinoma between January 1988 and April 1990 at the II and
IV Departments of Surgery of the Helsinki University Cen-
tral Hospital were included in the study. Patients with a
metachronous breast carcinoma less than 5 years previously
were excluded as it is not possible to determine the origin of
possible metastases. Nine synchronous breast carcinomas and
two carcinomas, which had metastasised were included in the
series. In patients with synchronous bilateral breast car-
cinoma, the statistical analysis was based on the breast with
the more severe stage. The mean age of the patients was 57
years (range 28-86 years) and the mean follow-up time was
2.7 years with a maximum of 4 years. The p-TNM
classification was done according to the pathologist's report
and following the international classification system (TNM
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Atlas, 1992). In the graphic survival representation Nl and
N2 patients were classified together because of the low
number of N2 patients (10). Patients with Tl tumours, were
usually treated with local resection only, unless the patient
preferred mastectomy. A local resection was done in 15% of
T2 carcinomas.
Tissue preparation
The breast specimens were laid on ice and frozen in liquid
nitrogen within 45 min. Sections for Ki-67 labelling, were
stored at - 20°. The acetone-fixed, air-dried sections were
incubated for 60 min at room temperature with the primary
Ki-67-antiserum (DakopattsO) diluted 1:10. The rest of the
staining procedure was performed using the avidin-biotin
method (ABC-Kit, Vector Laboratories@, Burlingame,
California). The result was visualised using AEC as
chromogen. Finally the sections were lightly counterstained
with Mayer's haematoxylin. For the immunohistochemical
demonstration of ER frozen sections were stained with the
ERICA kit (Abbott Laboratories®, Chicago, Illinois) accord-
ing to the instructions of the manufacturer.
All 327 breast carcinomas were stained for Ki-67, and 281
tumours were also successfully stained for ER. The cut-off
points for the Ki-67 and ER grading were arbitrarily chosen
at the beginning of the study before the outcome of the
carcinoma was known. The Ki-67 was graded as follows:
Ki-67 negative: at the most, rare nuclear staining. Ki-67
weakly positive (+): about 1-2% nuclear staining. Ki-67
moderately positive (+ + ): 3-10% nuclear staining. Ki-67
strongly positive ( + + + ) > 10% nuclei stained. For the ER
grade determination, ER up to 10% was scored as negative,
10-40% weakly positive, 40-70% moderately positive and
over 70% strongly positive. The percentage of Ki-67 and ER
positive cells was estimated by the same pathologist at the
time of the operation from at least five randomly chosen
medium power microscopic fields containing at least 2,000
cells. The Ki-67 was also independently scored by a biologist
without knowledge of the outcome of the disease or of the
score assessed by the primary observer. Metastatic disease
was confirmed by radiological and clinical examination.
Ki-67 status was correlated to other prognostic factors: ER
content, stage, tumour differentiation and nodal status. The
relationship between disease-free survival and Ki-67 status,
p-TNM, ER content and stage was also analysed.
Statistical methods
The disease-free survival was determined using a life table
analysis with a product limit method on all patients. The
correlation analysis was done with the logrank-chi-square
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method. Multivariate analysis including p-TNM, and
immunohistochemical determination of ER and Ki-67 was
performed by the Cox's proportional hazards model.
Results
Most tumours were ductal carcinomas (78%). Forty-one per-
cent were stage I and 49% were stage II carcinomas. A
breast resection was done in 46% of the patients with stage I
and in 15% of those with stage II carcinomas. The overall
resection rate was 61%. Most patients (137) were followed
up to 3 years and 72 patients up to 4 years. The mean
follow-up time was 2.7 years.
The disease-free survival (DFS) was significantly longer in
node negative than in node positive patients (P<0.005)
(Figure la), and the same applied to oestrogen receptor (ER)
positive vs negative patients (P<0.005) (Figure lb). The
DFS decreased with increasing stage (P<0.025) (Figure ic).
The DFS according to different prognostic factors, stage,
oestrogen receptor and node status, were separately examined
using a Cox's proportional hazards model showing that
oestrogen receptor (P<0.0001) and Ki-67 status (P<0.02)
as well as tumour size (P<0.0001) and nodal status
(P<0.006) were independent prognostic factors (Table I).
Table I Independent prognostic factors in breast carcinoma
Parameter P-value
Ki-67 <0.02
Oestrogen receptor <0.0001
Tumour size <0.0001
Nodal status <0.006
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Figure 1 a, Disease-free survival substratified by nodale status. Node positivity was associated with worse prognosis (P< 0.005).
b, The disease-free survival substratified by ER. The ER negative subgroup had the worst prognosis. (P< 0.005). c, the disease-free
survival substratified by stage.
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The overall patient survival according to Ki-67 expression
showed no significant differences between the different Ki-67
groups (Figure 2a). On the other hand, there was a difference
in the disease-free survival between Ki-67 negative and
strongly positives (+ + +) (x2 = 17.3, P<0.005) (Figure 2b).
There was no difference in the Ki-67 results obtained by the
two independent observers. The correlation with DFS was
the same. There were only small differences in the scores
(Figure 3).
Neither the distribution of the Ki-67 expression according
to the stage, nor the distribution of Ki-67 expression within
the different groups of oestrogen expression showed any
significant differences (data not shown). Likewise, the distri-
bution of the Ki-67 expression according to the nodal status
did not show statistically significant differences (data not
shown). The histologic grading of the specimens was not
done routinely, but to evaluate the correlation between Ki-67
and grade, a randomly chosen group of 40 specimens was
graded. There was a positive correlation between Ki-67 label-
ling and tumour grade (P = 0.007).
If the patients were divided into groups according to the
Ki-67 and ER expression to form different subgroups with
potentially different risks (Figure 4), patients with Ki-67
positive and ER negative tumours had the shortest DFS
(P<0.05). Patients with Ki-67 negative and ER positive
tumours had the longest DFS. The DFS was also signifi-
cantly shorter for Ki-67 positive and ER positive tumours as
compared to Ki-67 negative and ER positive tumours (Figure
4).
In an attempt to identify those stage I patients with poor
prognosis, the stage I patients with ER negative and Ki-67
positive tumours were compared with those with ER positive
and Ki-67 negative tumours. The difference in DFS between
these groups was not significant, probably due to a too short
follow-up time. On the other hand, in stage II tumours there
was a significant difference in the disease-free survival when
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Figure 3 Difference in Ki-67 score between two observers.
the same comparison was made for stage II tumours
(X2= 12.8 P<0.005), (Figure 5).
Discussion
Because of the short follow-up period of the patients we
chose to focus on the disease-free survival. Our study sug-
gests that determination of the proliferative activity of breast
carcinoma by immunohistochemical staining with the mono-
clonal antibody Ki-67 provides a useful prognostic indicator
fo the relapse-free period in patients with breast carcinoma.
The data suggest that if Ki-67 labelling is used alone as a
prognostic factor a useful cut-off point delineating a high-risk
group is 10% labelling nuclei, that is 'strongly positive' in
our study.
We found that patients with Ki-67 positive, ER negative
tumours had a clearly shorter disease-free survival than other
combinations of these two parameters, and it may be
relevant to routinely combine the results of these two
analyses in the pathologist's report. The histologic grading
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Figure 2 a, Overall survival substratified by KI-67. No statistical differences. b, Disease-free survival analysis substratified by
KI-67. The Ki-67 strongly positive group had the worst prognosis.
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Figure 4 Disease-free survival analysis substratified by KI-67 and ER. The Ki-67 positive ER negative subgroup had the worst
prognosis (P<0.005).
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Figure 5 Disease-free survival analysis, substratified by risk groups according to stage, ER and KI-67. In stage II patients, KI-67
positive and ER negative patients have the worst prognosis (P<0.005).
of the tumours in this series also showed a positive correla-
tion to Ki-67 labelling (P = 0.007) in agreement with
previous reports (Barnard et al., 1987; Gasparini et al., 1992;
Locker et al., 1992; Weikel et al., 1991).
From a practical point of view, one of the most important
goals is to identify stage I patients with a poor risk (about
10% of the total) who might benefit from some type of
adjuvant therapy. We failed to distinguish a subgroup of
such poor risk patients in stage I (ER negative/Ki-67
positive), perhaps because of the small number of patients
and the relatively short follow-up time of a maximum of 4
years. Neither has it been possible to single out those node
negative patients, which will get a relapse using the EGFR
expression, which is closely linked to cell proliferation
activity (Toi et al., 1991). Similar results for early relapses in
node negative patients have been obtained with her/neu
oncogene (Slamon & Clark, 1988). Cathepsin D has also
failed to predict disease-free survival in node negative
patients, while its predictive value was considerably streng-
thened when combined with ER-determinations (Granata et
al., 1991). Long term follow-up studies on stage I and node
negative patients show that a recurrence can occur decades
after the initial diagnosis. Those new methods which cannot
be applied to fixed archivel tissue still need some time to
show their value. In stage II tumours, including also node
negative patients, there was a significant difference in disease
free survival between Ki-67 positive/ER negative and ER
positive/Ki-67 negative (P<0.005). O'Reilly has described an
even more specific subdivision of patients with different prog-
nosis using the S-phase fraction (SPF) and tumour size
(O'Reilly et al., 1990). According to these results patients
with tumour greater than 1 cm with an SPF < 10% have a
5-year relapse-free survival of 78%, compared to 52% in
tumours of the same size with an SPF>10%. The higher
prognostic value of SPF compared to Ki-67 might be due to
the longer follow up time (median 8 years). The SPF value is
also higher in aneuploid tumours than in diploid tumours
(O'Reilly, et al., 1990) which might give SPF a better dis-
criminatory power than Ki-67. On the other hand, the Ki-67
scores are much higher in aneuploid carcinomas than in
diploid ones (Gasparini et al., 1991).
In conclusion, despite the relatively short follow-up period
of this study, our data suggest the potential value of Ki-67
labelling as a relatively simple and inexpensive method for
prognostic evaluation of patients with breast carcinoma. The
value of the method is enhanced if the result in the
pathologist's report is given in conjunction with the
immunohistochemical evaluation of oestrogen receptors.
Until recently the study of Ki-67 proliferation antigen has
been restricted to such cases, where fresh or frozen tissue is
available. Recently new antibodies have been developed
which also detect the Ki-67 antigen in paraffin embedded
tissues (Cattoretti et al., 1992).
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